Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin relapse prevention in dementia-related psychosis
NCT03325556Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of pimavanserin in dementia-related psychosis (DRP), sponsored by Acadia Pharmaceuticals. Started Sep 2017; status: completed.
02
Drugs
pimavanserin
03
Conditions
dementia-related psychosis (DRP)
Beyond the preview
Go deeper on NCT03325556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325556.